Which has preferable earnings & valuation, BVS or RXST?

Bioventus has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $576.30M 1.52 $22.73M $0.41 25.56 RxSight $134.48M 1.73 -$38.94M -$1.13 N/A

Is BVS or RXST more profitable?

Bioventus has a net margin of 4.94% compared to RxSight's net margin of -36.58%. Bioventus' return on equity of 29.97% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% RxSight -36.58% -17.01% -15.12%

Does the media refer more to BVS or RXST?

In the previous week, Bioventus had 1 more articles in the media than RxSight. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for RxSight. Bioventus' average media sentiment score of 0.33 beat RxSight's score of 0.00 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RXST or SSII?

In the previous week, SS Innovations International had 3 more articles in the media than RxSight. MarketBeat recorded 4 mentions for SS Innovations International and 1 mentions for RxSight. SS Innovations International's average media sentiment score of 0.72 beat RxSight's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SS Innovations International 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RXST or SGP?

In the previous week, RxSight and RxSight both had 1 articles in the media. RxSight's average media sentiment score of 0.00 equaled Spyglass Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CBLL or RXST?

RxSight has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $95.07M 7.80 -$53.41M -$1.63 N/A RxSight $134.48M 1.73 -$38.94M -$1.13 N/A

Is CBLL or RXST more profitable?

RxSight has a net margin of -36.58% compared to CeriBell's net margin of -63.51%. RxSight's return on equity of -17.01% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% RxSight -36.58% -17.01% -15.12%

Does the media favor CBLL or RXST?

In the previous week, CeriBell had 6 more articles in the media than RxSight. MarketBeat recorded 7 mentions for CeriBell and 1 mentions for RxSight. CeriBell's average media sentiment score of 0.10 beat RxSight's score of 0.00 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, BBNX or RXST?

RxSight has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 7.45 -$73.20M -$1.51 N/A RxSight $134.48M 1.73 -$38.94M -$1.13 N/A

Is BBNX or RXST more profitable?

RxSight has a net margin of -36.58% compared to Beta Bionics' net margin of -60.27%. RxSight's return on equity of -17.01% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% RxSight -36.58% -17.01% -15.12%

Does the media refer more to BBNX or RXST?

In the previous week, Beta Bionics had 7 more articles in the media than RxSight. MarketBeat recorded 8 mentions for Beta Bionics and 1 mentions for RxSight. RxSight's average media sentiment score of 0.00 beat Beta Bionics' score of -0.27 indicating that RxSight is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

RxSight (RXST) Competitors

$5.61 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.62 +0.00 (+0.09%)

As of 07/2/2026 07:59 PM Eastern

Compare

RXST vs. BVS, SSII, SGP, CBLL, and BBNX

Should you buy RxSight stock or one of its competitors? MarketBeat compares RxSight with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RxSight include Bioventus (BVS), SS Innovations International (SSII), Spyglass Pharma (SGP), CeriBell (CBLL), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does RxSight compare to Bioventus?

Bioventus (NASDAQ:BVS) and RxSight (NASDAQ:RXST) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, RxSight has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Bioventus currently has a consensus price target of $14.20, indicating a potential upside of 35.50%. RxSight has a consensus price target of $9.44, indicating a potential upside of 68.35%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

Bioventus has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56
RxSight	$134.48M	1.73	-$38.94M	-$1.13	N/A

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Bioventus had 1 more articles in the media than RxSight. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for RxSight. Bioventus' average media sentiment score of 0.33 beat RxSight's score of 0.00 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventus has a net margin of 4.94% compared to RxSight's net margin of -36.58%. Bioventus' return on equity of 29.97% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
RxSight	-36.58%	-17.01%	-15.12%

Summary

Bioventus beats RxSight on 13 of the 17 factors compared between the two stocks.

How does RxSight compare to SS Innovations International?

RxSight (NASDAQ:RXST) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, SS Innovations International had 3 more articles in the media than RxSight. MarketBeat recorded 4 mentions for SS Innovations International and 1 mentions for RxSight. SS Innovations International's average media sentiment score of 0.72 beat RxSight's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SS Innovations International	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SS Innovations International has a net margin of -20.69% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
SS Innovations International	-20.69%	-23.00%	-13.18%

RxSight has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.96, indicating that its stock price is 296% less volatile than the broader market.

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SS Innovations International has lower revenue, but higher earnings than RxSight. SS Innovations International is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.73	-$38.94M	-$1.13	N/A
SS Innovations International	$42.49M	17.80	-$12.13M	-$0.05	N/A

RxSight presently has a consensus target price of $9.44, indicating a potential upside of 68.35%. SS Innovations International has a consensus target price of $7.00, indicating a potential upside of 85.19%. Given SS Innovations International's higher possible upside, analysts clearly believe SS Innovations International is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

RxSight and SS Innovations International tied by winning 8 of the 16 factors compared between the two stocks.

How does RxSight compare to Spyglass Pharma?

RxSight (NASDAQ:RXST) and Spyglass Pharma (NASDAQ:SGP) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

78.8% of RxSight shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, RxSight and RxSight both had 1 articles in the media. RxSight's average media sentiment score of 0.00 equaled Spyglass Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyglass Pharma has a net margin of 0.00% compared to RxSight's net margin of -36.58%. Spyglass Pharma's return on equity of 0.00% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Spyglass Pharma	N/A	N/A	N/A

Spyglass Pharma has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.73	-$38.94M	-$1.13	N/A
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

RxSight currently has a consensus price target of $9.44, indicating a potential upside of 68.35%. Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 134.99%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Spyglass Pharma beats RxSight on 7 of the 11 factors compared between the two stocks.

How does RxSight compare to CeriBell?

CeriBell (NASDAQ:CBLL) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

78.8% of RxSight shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CeriBell had 6 more articles in the media than RxSight. MarketBeat recorded 7 mentions for CeriBell and 1 mentions for RxSight. CeriBell's average media sentiment score of 0.10 beat RxSight's score of 0.00 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 13.55%. RxSight has a consensus target price of $9.44, indicating a potential upside of 68.35%. Given RxSight's higher possible upside, analysts clearly believe RxSight is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

RxSight has a net margin of -36.58% compared to CeriBell's net margin of -63.51%. RxSight's return on equity of -17.01% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
RxSight	-36.58%	-17.01%	-15.12%

RxSight has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$95.07M	7.80	-$53.41M	-$1.63	N/A
RxSight	$134.48M	1.73	-$38.94M	-$1.13	N/A

Summary

RxSight beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does RxSight compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

RxSight has a net margin of -36.58% compared to Beta Bionics' net margin of -60.27%. RxSight's return on equity of -17.01% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
RxSight	-36.58%	-17.01%	-15.12%

Beta Bionics has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market. Comparatively, RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

RxSight has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.45	-$73.20M	-$1.51	N/A
RxSight	$134.48M	1.73	-$38.94M	-$1.13	N/A

Beta Bionics presently has a consensus price target of $19.70, indicating a potential upside of 17.54%. RxSight has a consensus price target of $9.44, indicating a potential upside of 68.35%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

78.8% of RxSight shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Beta Bionics had 7 more articles in the media than RxSight. MarketBeat recorded 8 mentions for Beta Bionics and 1 mentions for RxSight. RxSight's average media sentiment score of 0.00 beat Beta Bionics' score of -0.27 indicating that RxSight is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight beats Beta Bionics on 11 of the 17 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$232.24M	$7.57B	$7.16B	$12.48B
Dividend Yield	N/A	1.32%	2.66%	6.52%
P/E Ratio	-4.96	52.12	28.02	24.70
Price / Sales	1.73	49.46	540.37	99.49
Price / Cash	N/A	26.72	49.26	57.09
Price / Book	0.84	7.48	10.96	6.46
Net Income	-$38.94M	$159.19M	$3.57B	$337.01M
7 Day Performance	4.66%	-0.39%	2.12%	1.69%
1 Month Performance	12.20%	-0.43%	5.25%	3.81%
1 Year Performance	-57.50%	3.14%	33.29%	23.90%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	2.251 of 5 stars	$5.61 flat	$9.44 +68.4%	-57.5%	$232.24M	$134.48M	N/A	220	News Coverage High Trading Volume
BVS Bioventus	4.1166 of 5 stars	$9.41 -3.8%	$14.20 +50.9%	N/A	$785.44M	$568.09M	22.93	1,200	News Coverage Analyst Forecast
SSII SS Innovations International	2.2591 of 5 stars	$3.70 +4.7%	$7.00 +89.4%	-29.2%	$752.30M	$48.47M	N/A	4	Positive News Gap Up
SGP Spyglass Pharma	1.8149 of 5 stars	$22.39 +3.4%	$45.00 +101.0%	N/A	$751.74M	N/A	N/A	65	News Coverage Positive News
CBLL CeriBell	1.7202 of 5 stars	$19.32 -3.2%	$22.20 +14.9%	+3.3%	$735.28M	$89.06M	N/A	N/A	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors

RXST vs. BVS, SSII, SGP, CBLL, and BBNX

How does RxSight compare to Bioventus?

Summary

How does RxSight compare to SS Innovations International?

Summary

How does RxSight compare to Spyglass Pharma?

Summary

How does RxSight compare to CeriBell?

Summary

How does RxSight compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Competitors

RXST vs. BVS, SSII, SGP, CBLL, and BBNX

How does RxSight compare to Bioventus?

Which has more risk & volatility, BVS or RXST?

Do analysts recommend BVS or RXST?

Which has preferable earnings & valuation, BVS or RXST?

Do institutionals and insiders believe in BVS or RXST?

Does the media refer more to BVS or RXST?

Is BVS or RXST more profitable?

Summary

How does RxSight compare to SS Innovations International?

Does the media prefer RXST or SSII?

Is RXST or SSII more profitable?

Which has more volatility and risk, RXST or SSII?

Do institutionals and insiders believe in RXST or SSII?

Which has better earnings and valuation, RXST or SSII?

Do analysts prefer RXST or SSII?

Summary

How does RxSight compare to Spyglass Pharma?

Do institutionals & insiders believe in RXST or SGP?

Does the media prefer RXST or SGP?

Is RXST or SGP more profitable?

Which has higher valuation and earnings, RXST or SGP?

Do analysts prefer RXST or SGP?

Summary

How does RxSight compare to CeriBell?

Do insiders & institutionals believe in CBLL or RXST?

Does the media favor CBLL or RXST?

Which has more risk & volatility, CBLL or RXST?

Do analysts rate CBLL or RXST?

Is CBLL or RXST more profitable?

Which has stronger earnings and valuation, CBLL or RXST?

Summary

How does RxSight compare to Beta Bionics?

Is BBNX or RXST more profitable?

Which has more volatility and risk, BBNX or RXST?

Which has higher earnings and valuation, BBNX or RXST?

Do analysts prefer BBNX or RXST?

Do institutionals and insiders believe in BBNX or RXST?

Does the media refer more to BBNX or RXST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools